BiotechTube
Home/Pipeline/Regenerative Cell Therapy for Osteoarthritis

Regenerative Cell Therapy for Osteoarthritis

Knee Osteoarthritis

Phase 3Active

Key Facts

Indication
Knee Osteoarthritis
Phase
Phase 3
Status
Active
Company
InGeneron

About InGeneron

InGeneron is a private, clinical-stage biotech focused on developing point-of-care regenerative cell therapies for orthopedic injuries. Its core technology, the Transpose Ultra® system, enzymatically processes a patient's own adipose tissue to isolate a mixture of regenerative cells for immediate re-injection. With a lead program in rotator cuff tendinopathy and others in osteoarthritis, the company is pursuing a rigorous FDA approval pathway to address a large market of patients with chronic musculoskeletal conditions, differentiating itself from unregulated stem cell clinics.

View full company profile

Therapeutic Areas

OrthopedicsMusculoskeletal Disorders

Other Knee Osteoarthritis Drugs

DrugCompanyPhase
ProgenzaCambium BioPhase 1/2a
MAG200MagellanPhase 3
MUTI™ Knee ReplacementMerilCommercial
DUROLANEBioventusCommercial
XSTEMXintelaPhase I/IIa
Stempeucel®Stempeutics ResearchCommercial
Lipogems System for Knee OsteoarthritisLipogems InternationalPhase 3
Signature Cord Prime™Arugula SciencesPhase 1
Knee Osteoarthritis StudyArizona Research CenterNot Specified
4P0044Moving BiotechPhase 2a
Lorecivivint (inferred)Biosplice TherapeuticsPhase 3
ArthroCartArthro BiotechPreclinical